Introduction
Natural immunity against a pathogen derives from the integrated activation of the innate and adaptive immune systems (Table 1 ) [1] . Innate immunity arises after detection of specific pathogen-associated molecular patterns (PAMPs) through a variety of pattern recognition receptors (PRRs) [2] . The PRRs are able to detect common structural and functional features associated with different classes of microorganisms, and depending on the type of PAMP, activate specialised Antigen Presenting Cells (APCs) e.g., dendritic cells. Activation of innate immunity induces expansion of adaptive immune cells targeted to the particular threat through antigen-specific T-cell effector and antibody mechanisms. The immunological memory derived from this antigen-specific response persists and can react more rapidly upon subsequent infection [3] .
Immunisation is the strategy of stimulating the host's defence against a specific pathogen to establish immunological memory and thus protect against the consequences of infection. Some vaccines are made of whole viruses or bacteria which contain the microbial elements (PAMPs) that trigger the innate immune response required to initiate a suitable adaptive response. However, a whole-pathogen approach may not be feasible, practically or from a safety perspective, or desirable, especially if the agent is very reactogenic or tumorogenic. In such cases, partial fractionation may reduce reactogenicity or tumorgenicity by removing some pathogen components. Alternatively, recombinant DNA technology and biotechnology, or chemical purification can be used to produce a subunit of the pathogen as the vaccine antigen. The latter approaches require in-depth knowledge of the biology of the pathogen to identify the immunologically-relevant vaccine component(s). Since purified proteins usually demonstrate poor immunogenicity by themselves, adjuvants are used to enhance and modulate the immune responses by providing innate/PAMP triggers, thereby driving a protective response to the pathogenic threat. Combining the correct antigens and adjuvants to optimise the subsequent downstream adaptive immune response is a crucial task in the development of any new vaccine. Here we discuss the key principles and challenges faced in the development of vaccines targeting a diverse set of pathogens from concept to clinical trial in humans.
Pathogen life-cycle and epidemiology
Detailed knowledge of the biology and structure of the pathogen, its interaction with cellular receptors and its disease-causing mechanisms is important in order to identify antigens suitable for disease prevention. For some microorganisms, characteristics that differentiate commensal from pathogenic forms may need to be identified. Where the key subunit immunogens, e.g., capsule polysaccharides or virus surface proteins, are not conserved, or broad cross-reactive immunity cannot be generated (e.g., pneumococcus or human papilloma virus [HPV] , Box 1 [3] [4] [5] ), it may be necessary to prioritise the most common or the most medically important strains or serogroups. These often vary geographically or temporally: understanding the epidemiology of the disease is crucial to identifying the target antigens. The selection of serotypes is based on complex modelling involving serotype distribution, value and reimbursement, and the number of different subunits the vaccine may realistically contain based on costs and complexity of manufacture [6] . Where the epidemiology indicates a constrained distribution, a vaccine providing relevant -but less broad -strain coverage may be preferred on the grounds of cost or availability [7] . In some circumstances, such as for seasonal influenza, variability of the key antigens is unavoidable and a new vaccine is made each year.
Knowledge of the route of entry and subsequent replication sites of the pathogen is essential. This is because protection against pathogens entering via the respiratory (influenza, pneumococcus), gastrointestinal (Salmonella) or genital tracts (Herpes simplex virus [HSV] or human immunodeficiency virus [HIV] ), or entering the bloodstream by injury/injection (hepatitis B/C) or mosquito bite (Malaria, Box 2 [8] [9] [10] ), may require different vaccination strategies. To take one example, the immune response after natural malaria infection is considered to be predominantly directed against the blood stage of the pathogen but some vaccines have shown that it is possible to induce effective immunity by targeting the pre-erythrocytic stage, e.g. during sporozoite stage and the liver stage of the pathogen [8] [9] [10] . Similarly, prevention of the reactivation of infection may require different strategies to preventing primary infection. Special cases in vulnerable populations include postpartum infections such as group B streptococcus, and antenatal/perinatal infection such as hepatitis B (HBV) and HSV, as well as persistent virus such as Varicella zoster virus (VZV) and cytomegalovirus (CMV).
The clinical manifestations of the disease of interest and potential outcomes in the natural setting will also influence the vaccine requirements. For example, some pathogens, such as pneumococcus, can cause multiple clinical syndromes (invasive disease, pneumonia and otitis media), while dengue virus-associated diseases are substantially more serious when antibodies to one of the four types are already present [11] .
Knowledge of the demographics of infection (poverty, overcrowding versus delayed exposure in wealthier countries), specific risk groups and age-specific infection rates determine which population to immunise, and at what age. Having clear diagnostic criteria is fundamental and increasingly these diagnostic approaches include the capacity to identify both pathogen and serotype. Partner diagnostics are now being developed to support new vaccines. If the accuracy of diagnosis is poor, then the frequency of infection may be grossly under-or over-estimated, which has implications for understanding the disease burden to be prevented, and the impact of the vaccine after it is used.
The breadth of challenge for successful vaccine development is illustrated by comparison of the diversity of structure, polymorphism, natural history of infection and the consequence for human health of oncogenic HPV (Box 1), Plasmodium falciparum (responsible for the most aggressive malaria) (Box 2), and haemorrhagic Ebolavirus (Box 3 [12] [13] [14] ).
Natural immune control & escape
Human pathogens show enormous diversity in their biology, differing in the type of infection they induce (acute, chronic, latent), tissue target (skin or mucosal infections of the gastroin- testinal, respiratory and urogenital tracts, infections in specific non-mucosal target tissues or organs such as the meninges, blood stream or liver) and location (intracellular versus extracellular). Many pathogens also show considerable genetic diversity within their species or virus type. In most cases, infection is met by a timely innate and subsequent adaptive immune response leading to control and elimination of the infection. However, pathogens often express a number of virulence determinants that allow the pathogen to avoid immune defences, facilitating infectivity and transmission. These include stealthy infection, whereby pathogen-encoded determinants bind to specific cellular receptors allowing cell entry without alerting the immune response (viruses and some bacteria), production of proteins, enzymes and microRNAs that inhibit host-pathogen recognition mechanisms and innate immune effector responses (influenza A) [15] , and production of structures such as polysaccharide capsules that inhibit immune effectors such as complement (Neisseria meningitidis) [16] . Other virulence determinants are structural changes that promote intracellular sequestration (Escherichia coli) [17] , high rates of mutation that ensure that antibodies stimulated during earlier infection remain ineffective (influenza, HIV, hepatitis C) [18] , expression of toxins that cause tissue destruction and modulate the immune response (pneumococcus) [19] , mimicry of host proteins (meningococcus serotype B) [20] , and latent stages that remain undetected by the immune system (herpes viruses, HIV, tuberculosis) [21] . Detailed knowledge of immune escape strategies used by individual pathogens is important for developing effective vaccines against them.
A major goal in vaccine development is determining the immune response that must be elicited by vaccination; the socalled 'correlate of protection'. Antibody-mediated neutralisation has traditionally been the major target of vaccines, as many pathogens require receptor-mediated binding to cells and/or fusion, or mediate pathogenicity by producing specific toxins; all of which can represent protective antibody targets. Newer vaccines targeting more complex pathogens are designed to enhance other aspects of the innate and adaptive response. The relative contribution of antibodies, CD4+ and CD8+ T-cells and innate immunity to protection against infection needs to be evaluated and transposed to vaccine-induced primary immunity or to immunotherapy of persistent or recurrent infections. The role of selected T-cellmediated effector functions, including pro-inflammatory cytokine production and help for antibody-mediated immunity, also needs to be determined. Licensed but yet to be shown to be more effective than quadrivalent or bivalent in protection versus CIN3 Therapeutic vaccines: for treatment of infections or early cancers by targeting E6 and E7 using a plethora of approaches. Recent DNA vaccine delivered by electroporation met primary clinical endpoint in CIN3 [5] The relative importance of each immune mechanism varies for any given pathogen. For example, antibodies are thought to play a major role in preventing HBV and influenza infections, whereas Tcells, especially CD4+ T-cells are believed necessary for control of tuberculosis. For pathogens such as HIV and influenza virus which are highly variable, antigenically broad neutralising antibodies capable of targeting common epitopes are now being explored.
Although non-neutralising antibodies can bind to a virus, they were thought not to significantly affect virus capacity to infect cells and replicate. Exceptions are now being identified as antibodies capable of directing immune killer cells to the pathogen-infected target have been found to be important [22] . Enhancing antibodies that result in increased infection have also been reported, so optimising antigen structure is a key aspect of vaccine development.
The uptake and presentation of pathogen-derived antigens to Tcells by APCs (primarily dendritic cells in the primary immune response, and monocyte-derived cells and B-cells in subsequent responses) can be exploited by vaccination [23] . New generation vaccine adjuvants target these APCs via their PRRs, enhancing their ability to present antigen, migrate and stimulate T-and B-cell effector cells [24, 25] . These adjuvants can replace and even exceed the effects of natural pathogen PAMPS (e.g., the adjuvanted Herpes zoster vaccine [26] ). The clinical outcome to be prevented needs to be defined (systemic infection, mucosal disease, reactivation, severe disease). For many diseases, data on surrogate markers or correlates of protection may only be attainable after licensure when the vaccine is used in large populations. Nevertheless, immunologic studies in clinical trials of partially effective vaccines are especially important in guiding future improvement of the candidate. Such trials could potentially identify crucial mechanisms by comparing vaccinees with breakthrough infections to those apparently protected.
As examples, the evasion of immunity for oncogenic HPV derives from stealthy infection and virus production without cell death plus viral gene modulation blunting antigen presentation and effector function (Box 1); for P. falciparum there is immense genetic polymorphism and a requirement for distinct immune responses at each stage of a very complex life-cycle (Box 2); for Ebola infection, which can neutralise key innate immune defences such as interferon, the impact is so devastating in immune-naïve individuals there is only a low rate of natural immune-mediated survival, although this may be protective in those who do survive (Box 3). For HPV, natural immune clearance is primarily due to cell-mediated immunity whereas for P. falciparum and Ebola the characterisation of the key components of natural immunity is incomplete and/or not fully understood. Note that the relative importance of immune mechanisms may differ for protection from disease and for clearance of infection. 
Antigen selection & vaccine formulation
Classically, 'protective' antibodies elicited by natural infection are studied to identify the main target(s) of the effective immune response, usually proteins (toxins [such as diphtheria and tetanus or filamentous haemagglutinin in pertussis vaccines]) or carbohydrates (capsular polysaccharides [pneumococcus, meningococcus]). Potential candidates are analysed for suitability as vaccine antigens, including determining their homology with human proteins and potential inherent toxicity. Detoxification may be required before an antigen (for example, pertussis toxin) can safely be administered to humans, but some detoxification methods may destroy epitopes in the process, and impact immunogenicity [27] . Furthermore, purification of antigens away from other viral and bacterial components such as lipids and nucleic acids may exclude PAMPS, altering the nature of the immune response. Initial in vitro studies may evaluate antigen-antibody binding capacity and function, and early investigation of the immune response to the candidate antigen may be assessed in animals.
However, immunity is not always mediated via a humoral response (e.g., malaria [Box 2] or tuberculosis); rapid evolution of the pathogen may mean that potential antigens change rapidly (influenza and HIV); the antigen may be similar to human proteins, potentially increasing the risk of autoimmunity (meningococcal serogroup B capsule, group A streptococcal capsule); a complex life-cycle may mean that the host is exposed to different antigens at different times in the life-cycle (malaria, Box 2), or that reactivation occurs in a previously infected host (VZV, [28] . New technologies, such as reverse vaccinology [6] , are required to identify candidate antigens for these challenges where the expression of surface structures is predicted, based on inferred protein sequences from the pathogen's genome.
Vaccines need to be efficiently produced and deliverable in a form acceptable to the recipient. The earliest vaccines used whole organisms; either alive (attenuated versions of the pathogen, or related but less virulent organisms that could induce crossreactive immunity without inducing disease), or dead. Whole organisms have the advantage of being highly immunogenic and typically stimulate a response similar to that generated by natural infection. Unfortunately, they may also generate pathology similar to that induced by the natural infection; and in cases where natural infection does not generate protective immunity, a wholeorganism vaccine may be likewise ineffective. There is the secondary limitation that whole organisms are complex mixtures of proteins, lipids and carbohydrates, which greatly complicates production, characterisation and quality control of the final vaccine.
For these reasons, the focus has shifted toward vaccines containing specific antigens, which can be characterised at the molecular level. The properties of the most commonly-used vaccine technologies are shown in Table 2 . With the exception of whole organisms, all of these technologies rely on presenting selected, key antigens that will ensure a strong, persistent and broad immune response of the kind needed for protection, while avoiding or minimising reactogenicity. Purified antigens can sometimes be poorly immunogenic, so the first task is to choose a vaccine delivery system that boosts immunogenicity and promotes a protective immune response. It is also essential that the technology selected is economically viable. Since prophylactic vaccines are typically administered to very large numbers of healthy individuals they are among the most price-sensitive of all medical products, and the acceptable price depends greatly on the target population: a vaccine for childhood malaria, most needed in some of the poorest countries in the world, faces different design constraints than one against, for example, zoster, which is targeted primarily toward [12, 13] . Problem is the difficulty in testing in humans in view of erratic epidemics [14] . Role of T-cells needs to be clarified [29, 30] . In the absence of predictive models for these interactions, there is currently no alternative to time-consuming (and expensive) in vivo testing. Alum, the oldest adjuvant (aluminium hydroxide or aluminium phosphate) has been in use for over 90 years. While alum has demonstrated an excellent safety record [31] , it has been assessed primarily on its ability to promote humoral immune responses, with little or no attention paid to the cellular immunity induced [32] . Early emulsions, such as Freund's complete adjuvant, generated highly effective cellular immune responses; but also unacceptable side effects [33] .
When molecular mechanisms involved in the induction of the immune response to adjuvants were studied and understood in the 1990s, it was realised that immunogenicity and immunopathology were promoted by different, partially overlapping immune pathways. This allowed for the development of new adjuvants that combined enhanced immunogenicity with acceptable reactogenicity. Several of these are now used in products that are licensed [34, 35] and typically include multiple components to stimulate a broad range of immune responses (Table 3 [32, [36] [37] [38] [39] [40] ).
Concurrent with the development of better adjuvants for vaccine delivery, other vehicles that allow the tight association of antigen and immunomodulators have been developed. These include, but are not limited to, toxoids, virosomes, liposomes, immunostimulating complexes (ISCOMS) and micro-or nano-particles. The first two are already used in commercially-available vaccines (Table 3) , while the rest have provided promising clinical data (reviewed in [41] ). Toxoid-conjugated vaccines, though employing different technologies to those discussed above, utilise the same general concept; the combination of a detoxified, but immunogenic microbial PAMP able to stimulate innate and T-cell dependent responses, linked to antigenic polysaccharide targets, which can generate strong B-cell responses and antibody production. This approach has been used to generate licenced vaccines against serious invasive bacterial infections (Haemophilus influenzae type b, N. meningitidis, Streptococcus pneumoniae) using toxoids derived from either tetanospasmin of Clostridium tetani or the diphtheria toxin of Corynebacterium diphtheria, which have been shown to generate more robust and long-lived antibody responses than the polysaccharide targets alone, presumably due to the activation of T-cell help [42] . Other conjugate vaccines, such as a typhoid vaccine using a modified exoprotein A from Pseudomonas aeruginosa as the toxoid are under development [43] .
Virosomes, liposomes and ISCOMS, although different in structure and immunostimulatory capacity, are built around the concept of a lipid vesicle (the lipids used are themselves weakly immunostimulatory) to which can be added both antigenic targets and immunomodulatory molecules [37] . The physical properties and size of the vesicle can be tailored to requirements depending on the lipid composition and production methods, as can the ionic charge. These factors influence the ability of the delivery system to form depots, bind to antigen-presenting cells and the antigen loading of the delivery system [37] . In many ways, these adjuvants mimic natural enveloped bacteria or viruses, with a lipid envelope and associated proteins. This process is taken a step further by virus-like particles (VLP), where the lipids and antigenic target are derived directly from the pathogen in question, producing a delivery vehicle that resembles a pathogen but without the genes required to initiate infection [44] .
Vaccine preclinical & clinical testing
One of the most challenging aspects of vaccine design remains assessing the efficacy or effectiveness of new vaccine formulations. The clinical assessment of vaccines is discussed in more detail in [58] . In some cases, where clear correlates of immunity can be observed (such as for measles, where the link between antibody level and clinical outcome is indisputable [45] ), or animal models which accurately mimic human disease, non-clinical estimates of efficacy can be made with a high degree of certainty: unfortunately, while having an immune correlate is desirable, and extremely helpful, they are mostly lacking in the early phases of Transient NF-jB, cytokine and chemokine response, increased numbers and efficiency of activated dendritic cells leading to enhanced antibody responses [38] Human papillomavirus vaccine hepatitis B (pre-and haemodialysis patients) MF59
Oil-in-water emulsion with squalene Enhances antigen uptake by APCs, cytokine and chemokine response enhancing the local immune response, increased quantity and diversity of the antibody response [36] Influenza (seasonal and pandemic)
Virosomes Phospholipids: lecithin, cephalin The virosome structure functions to enhance update by APCs. Stimulates mononuclear cells toward a Th1 cytokine profile [37] Influenza, hepatitis A QS-21: Quillaja saponaria Molina: fraction 21. (Antigenics Inc, a wholly owned subsidiary of Agenus Inc., Lexington, MA, USA). MPL: 3-deacylated monophosphoryl lipid. CpG7909: an immunostimulatory nucleotide. DTaP -combined diphtheria-tetanus acellular pertussis vaccine clinical development [46] . Although a specific immune response (induced either by vaccination or natural infection) is generally observed in protected individuals, it is often difficult to identify the precise immune mechanism(s) responsible for efficient protection from the large array of elicited effectors (antibodies, cytokines, T-cells and so on). As an example, the effectiveness of HBV vaccines is measured by the ability to induce an antibody response against the HBV surface antigen (HBsAg) of P10 mIU/ml of blood) [45, 47] based on the observation that individuals with such a response were protected from infection. Long-term follow-up indicated that in some individuals antibody levels waned with time; but these individuals remained protected from infection [48] . Booster vaccinations revealed that vaccinated individuals displaying low to undetectable levels of serum antibodies were nevertheless able to mount a robust recall response, indicative of a persistent and protective immune memory despite a waning humoral response [49] . The presence of an antibody response after vaccination (or infection) demonstrates that an immune response has been generated, but in this case, there is no direct correlation between the magnitude of the antibody response and the degree of protection. In other words, antibody production in response to vaccination is an indicator of immunogenicity, not efficacy. This may be due to the fine specificity of the protective antibody response, not the total level of antibody produced. Nonetheless, long experience with vaccines such as those against pneumococcus and influenza, has proved that the linkage between immunogenicity and vaccine effect is so robust, that for these vaccines, generation of a sufficiently strong and mature antibody response is accepted for licensure, even if the antibody is only part of the protective immune response [50] . The ultimate test of vaccine efficacy is of course, protection in humans; but when choosing which vaccine candidates to take into clinical trials, other surrogate approaches are needed. The critical points along the preclinical pathway include detailing the hostpathogen interaction, understanding the protective immune mechanisms involved and selecting an appropriate antigen and adjuvant to achieve the desired immune response. Subsequent steps involve the production of the antigen, and a compatible vaccine delivery system, followed by the development of immune readouts and toxicological tests to assess the safety and performance of the candidate vaccine construct under preclinical evaluation.
If a plausible mechanism of protection or suitable surrogate markers can be identified, animal models can be informative with regard to protective effects and antigen recognition, even if they do not replicate the human disease closely enough to be predictive [51] . Non-human primate and rodent models of Ebola infection exist, and since efficacy studies are not feasible in view of the sporadic nature of Ebola outbreaks, evidence gained from animal models has been considered to support vaccine licensure [14] . By contrast, no good animal model for HIV infection has been identified, though infection of non-human primates with simian immunodeficiency virus is a useful surrogate model. However, improvements to this model and the development of a more affordable animal model remains a priority [52] . Animal models have also proven their value for the assessment of vaccine safety and toxicology, even though preclinical toxicology studies are typically relatively small, and powered to identify direct toxic effects [53] . In cases where an effective treatment is available for the disease, human challenge studies where volunteers agree to be exposed after vaccination is the closest possible model to human disease: this approach has been successfully used in malaria vaccine development (Box 2), and is being explored for other diseases that lack suitable animal models such as typhoid fever [54] .
Some approaches used for vaccine design and testing are presented in the examples provided in Boxes 1-3.
HPV vaccines
The licensed HPV vaccines are based on VLP technology [44] plus an adjuvant, to generate a stronger antibody response than natural infection. The quadrivalent vaccine uses alum and in the bivalent HPV vaccine, this is further supplemented by the use of detoxified monophosphoryl lipid A (MPL), a modified membrane component common in Gram-negative bacteria, which binds to TLR4 and stimulates strong cell-mediated immunity [35, 55] . The combination of MPL and aluminium induces higher antibody levels than aluminium alone [38] . The value of more complex adjuvants can be seen in direct comparisons of the antibody induced by alum-adjuvanted antigens and the combination delivery system and may explain the broad cross-reactivity seen with this vaccine, and its ability to provide protective immune memory significantly superior to that derived from natural infection [24, 25, 56] . Consistent with this, HPV vaccines' immunogenicity and capacity to induce long lasting responses were initially tested in HPV-naïve young women, in which antibody levels were found to exceed those produced by individuals naturally exposed to HPV. Subsequent clinical trials in HPV-naïve young women used a surrogate endpoint of cancer, high grade cervical intra-epithelial neoplasia (CIN3), to establish efficacy but as yet there is no immune correlate of protection with antibody levels. Additionally, the principle vaccination target group for prevention of cervical cancer is young girls before sexual debut, and thus licencing depended on bridging studies showing greater immunogenicity in this cohort.
Even when there are licenced vaccines against a pathogenic threat, there is almost always room for improvement. Thus HPV VLP vaccines containing more oncogenic types, or even therapeutic vaccines based on HPV oncogenes, which could also be prophylactic, are strategies driving future developments (Box 1).
Malaria vaccines
The first vaccine against P. falciparum to successfully complete phase III trials (RTS,S) combines a fusion construct of epitopes from the Circumsporozoite Protein with HBsAg adjuvanted with AS01, a liposomal suspension of the immune enhancers MPL and QS21 (Box 2). The malarial vaccine RTS,S may be licenced based on the available protection data, but there will be a need to further improve the longevity of the immune response and vaccine impact to encourage widespread vaccination: for example, while the vaccine offers some protection from malaria caused by P. falciparum, a vaccine against P. vivax, the second most important cause of malaria, is also of high priority [57] .
Herpes zoster vaccine
For herpes zoster, two vaccine strategies have been shown to stimulate waning cell mediated immunity to earlier infection by the VZV: high dose whole attenuated virus and a subunit adjuvanted vaccine which aims to enhance cell-mediated immunity (Supplementary Box 1) . The high efficacy in older people of the subunit VZV/adjuvant vaccine compared with the results from independent trials with the highly concentrated attenuated viral vaccine is very encouraging for overcoming age-related declines in immune responses [26] .
Dengue vaccines
There are several candidate dengue virus vaccines in various stages of testing (Supplementary Box 2) . A chimeric viral vaccine using yellow fever as a backbone has been licenced in some countries and induces neutralising antibodies to all four serotypes, but optimal use appears to require priming with yellow fever vaccine one year previously. For dengue virus vaccines adopting a goal of preventing hospitalisation rather than complete prevention of disease may influence future developments [11] .
Ebola vaccines
For Ebola there are more than 10 candidate vaccines under development. The most advanced are recombinant adeno-and vesicular-stomatitis virus (VSV) encoding EBOV glycoprotein. Ebola vaccination strategies based on available hybrid recombinant viruses have been catapulted into clinical testing, driven by the impact of the recent devastating Ebola outbreak in several African countries. The rVSV-ZEBOV vaccine induces elevated levels of antibodies in primate models and vaccination trials in Africa show 75% efficacy but with high reactogenicity (Box 3). There are many challenges for comprehensive testing of Ebola vaccines in view of the epidemic nature of the disease. The wider consequences of viral persistence after apparent recovery are not yet fully understood and the analysis of the role of cellular immunity in recovery may be critical to future vaccine design.
Conclusion
Vaccine development is a complex multidisciplinary activity, combining understanding of host-pathogen interactions at the molecular level, with clinical science, population-level epidemiology and the biomechanical requirements of production. The basis is an understanding of which immune processes shape disease and protection, and how these vary between individuals, risk groups and populations. That knowledge in turn informs the selection of antigenic targets, and the adjuvants/delivery systems used to shape the immune response induced by the vaccine; which in turn determines the manufacturing requirements and the clinical trial design. The ultimate goal is an affordable vaccine that generates strong and lasting immunity with the fewest possible side effects, implemented without the need for expensive cold chains.
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